Abstract
Adiponectin appears to be an important modulator for metabolic and vascular diseases. A case-controlled study was designed to measure plasma adiponectin levels and investigate the effects of rosiglitazone on adiponectin levels in type 2 diabetic patients with proteinuria. Sixty-four patients (mean age, 46.1±4.6 yr; 30 male, 34 female) and 26 healthy volunteers (mean age, 45.3±4.8 yr; 14 male, 12 female) were included. Patients with proteinuria were treated with 4-mg/d rosiglitazone (n = 21, 10 males, 11 females) for 4 wk. Adiponectin levels in patients were significantly lower than those of controls (p<0.001). There were significant negative correlations between adiponectin concentrations and insulin levels as well as homeostasis model assessment (HOMA) index in patient’s group (r=−0.538, p<0.001; r,=−0.393, p=0.001, respectively). There was also a significant negative correlation between plasma adiponectin concentrations and the degree of proteinuria (r=−0.526, p=0.002). Plasma adiponectin levels in patients with proteinuria ?(n=31; 3.91±2.57 µg/mL) were significantly lower than those without proteinuria (n=33; 10.15±1.97 µg/mL) (p<0.001). After the treatment period, adiponectin levels significantly increased (p<0.001) and proteinuria, plasma insulin, and HOMA indexes significantly decreased in treatment group (p<0.001, p<0.001, p<0.001, respectively). The results suggest that adiponectin is inversely correlated with proteinuria and treatment with peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist rosiglitazone both corrects proteinuria and increases the low adiponectin levels in diabetic patients.
Similar content being viewed by others
References
Cooper, M. E. (1998). Lancet 352, 213–219.
Vlassara, H. (1996). Kidney Int. 49, 1795–1804.
Remuzzi, G. and Bertani, T. (1998). N. Engl. J. Med. 339, 1448–1456.
Lebovitz, H. E. and Banerji, M. A. (2004). Eur. J. Pharmacol. 490, 135–146.
Imano, E., Kanda, T., Nakatani, Y., et al. (1998). Diabetes Care 21(12), 2135–2139.
Nakamura, T., Ushiyama, C., Suzuki, S., et al. (2001). Diabet. Med. 18(4), 308–313.
Nicholas, S. B., Kawano, Y., Wakino, S., Collins, A. R., and Hsueh, W. A. (2001). Hypertension 37, 722–727.
Szalkowski, D., White-Carrington, S., Berger, J., and Shang, B. (1995). Endocrinology 136, 1474–1481.
Maeda, K., Okubo, K., Shimomura, I., Funahashi, T., Matsuzawa, Y., and Matsubara, K. (1996). Biochem. Biophys. Res. Commun. 221(2), 286–289.
Arita, Y., Kihara, S., Ouchi, N., et al. (1999). Biochem. Biophys. Res. Commun. 257, 79–83.
Ouchi, N., Kihara, S., Arita, Y., et al. (1999). Circulation 100, 2473–2476.
Hotta, K., Funahashi, T., Arita, Y., et al. (2000). Arterioscler. Thromb. Vasc. Biol. 20, 1595–1599.
Shimabukuro, M., Higa, N., Asahi, T., et al. (2003). J. Clin. Endocrinol. Metab. 88(7), 3236–3240.
Ouchi, N., Kihara, S., Arita, Y., et al. (2001). Circulation 103, 1057–1063.
Ouchi, N., Ohishi, M., Kihara, S., et al. (2003). Hypertension 42(3), 231–234.
Maeda, N., Takahashi, M., Funahashi, T., et al. (2001). Diabetes 50(9), 2094–2099.
Hirose, H., Kawai, T., Yamamoto, Y., et al. (2002). Metabolism 51(3), 314–317.
Yang, W. S., Jeng, C. Y., Wu, T. J., et al. (2002). Diabetes Care 25(2), 376–380.
Koshimura, J., Fujita, H., Narita, T., et al. (2004). Biochem. Biophys. Res. Commun. 316(1), 165–169.
Zoccali, C., Mallamaci, F., Panuccio, V., et al. (2003). Kidney Int. Suppl. 84, S98-S102.
Guan, Y. and Breyer, M. D. (2001). Kidney Int. 60, 14–30.
Herrmann, S. M., Ringel, J., Wang, J. G., Staessen, J. A., and Brand, E. (2002). Diabetes 51, 2653–2657.
Mukherjee, R., Jow, L., Croston, G. E., and Paterniti, J. R. Jr. (1997). J. Biol. Chem. 272(12), 8071–8076.
Gurnell, M., Savage, D. B., Chatterjee, V. K., and O’Rahilly, S. (2003). J. Clin. Endocrinol. Metab. 88, 2412–2421.
Lebovitz, H. E. (2002). Am. J. Cardiol. 90(5A), 34G-41G.
Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y., and Walsh, K. (2003). Curr. Opin. Lipidol. 14(6), 561–566.
Zoccali, C., Mallamaci, F., Tripepi, G., et al. (2002). J. Am. Soc. Nephrol. 13(1), 13–141.
Ruggenenti, P., Perna, A., Mosconi, L., Pisoni, R., and Remuzzi, G. (1998). Kidney Int. 53, 1209–1216.
Paisley, K. E., Beaman, M., Tooke, J. E., Mohamed-Ali, V., Lowe, G. D., and Shore, A. C. (2003). Kidney Int. 63, 624–633.
Maeda, N., Takahashi, M., Funahashi, T., et al. (2001). Diabetes 50, 2094–2099.
Phillips, S. A., Ciaraldi, T. P., Kong, A. P., et al. (2003). Diabetes 52(3), 667–674.
Faraj, M., Havel, P. J., Phelis, S., Blank, D., Sniderman, A. D., and Cianflone, K. (2003). J. Clin. Endocrinol. Metab. 88(4), 1594–1602.
Combs, T. P., Wagner, J. A., Berger, J., et al. (2002). Endocrinology 143(3), 998–1007.
Pajvani, U. B., Hawkins, M., Combs, T. P., et al. (2004). J. Biol. Chem. 279(13), 12152–12162.
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C. (1985). Diabetologia 28, 412–419.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yilmaz, M.I., Sonmez, A., Caglar, K. et al. Peroxisome proliferator-activated receptor γ (PPAR-γ) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Endocr 25, 207–214 (2004). https://doi.org/10.1385/ENDO:25:3:207
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:25:3:207